Arthur Hayes, newly pardoned, has joined the board and acquired a major stake in a private stem cell company where he has been a long-term patient; his move links crypto capital to longevity biotech and signals growing investor interest in life-extension ventures.
-
Hayes took a board seat and sizable equity stake in a rebranding stem cell firm after his presidential pardon.
-
He has used the company’s clinics in Mexico and Bangkok for over a year and cites longevity as a primary motive.
-
His family office, Maelstrom, continues to fund crypto infrastructure and Bitcoin grants while expanding into longevity investments.
Arthur Hayes stem cell investment: Hayes joins the firm’s board and buys major stake after pardon — read how crypto capital is moving into longevity. Learn more.
What is Arthur Hayes’ role in the stem cell company?
Arthur Hayes has accepted a board seat and acquired a significant equity stake in a privately held stem cell company, and he has been a patient at the company’s clinics in Mexico and Bangkok for more than a year. The change follows his March presidential pardon and marks a shift from derivatives trading to longevity biotech investment.
How did Hayes become involved with the stem cell firm?
Hayes told Bloomberg he sought treatments to extend healthy lifespan and that regulatory frameworks in some countries have relaxed, enabling broader clinical access. The company is currently rebranding and declined comment through spokespeople; Hayes framed the move as both a personal health decision and a strategic investment by his family office, Maelstrom.
Arthur Hayes, pardoned in March, has joined the board and acquired a major stake in a stem cell company where he has been treated; his family office continues active crypto investments.
Arthur Hayes — co-founder of the derivatives exchange BitMEX and a prominent figure in crypto finance — accepted a board position and a substantial equity stake in a privately held stem cell firm. The move came after a presidential pardon in March that removed his prior Bank Secrecy Act conviction.
Hayes has been a patient at the company’s clinics in Mexico and Bangkok for over a year and said his primary motivation is longevity. “I want to live as long as possible, as healthy as possible,” he told reporters.
Hayes thanks Trump after pardon. Source: Arthur Hayes
Crypto wealth has increasingly flowed into longevity and biotechnology. In 2021, Vitalik Buterin donated $25 million in Shiba Inu tokens to the Future of Life Institute and contributed over $350,000 to the SENS Research Foundation to support aging research. Former Coinbase executive Balaji Srinivasan co-founded the genomics company Counsyl, while Coinbase CEO Brian Armstrong co-founded NewLimit, which raised substantial funding this year.
Hayes’ family office, Maelstrom, remains active in crypto: it backs companies that hold digital assets on corporate treasuries and funds open-source Bitcoin work. Last year Maelstrom launched a Bitcoin grant program offering $50,000–$150,000 annually, and up to $250,000 per developer, to strengthen Bitcoin’s scalability and privacy.
Frequently Asked Questions
Did the presidential pardon enable Hayes’ new role?
Yes. The pardon in March removed Hayes’ conviction tied to weak AML controls at BitMEX, clearing legal obstacles and enabling his public role as a board member and investor in the stem cell company.
Why are crypto investors moving into longevity?
Many crypto investors are directing capital toward longevity due to rapid scientific progress, potential high returns, and personal interest in life-extension. Notable figures like Vitalik Buterin and Brian Armstrong have publicly supported longevity and genomics initiatives.
Key Takeaways
- Board appointment and stake: Hayes accepted a board seat and significant equity in a rebranding stem cell firm after his pardon.
- Personal and strategic motives: He has been a patient at the company’s clinics and cites longevity as both a personal goal and investment thesis.
- Ongoing crypto activity: Maelstrom continues to fund Bitcoin grants and to back firms that hold digital assets, bridging crypto capital with biotech.
Conclusion
Arthur Hayes’ entry into a stem cell company — as both patient and investor — underscores a broader trend of crypto capital flowing into longevity biotech. COINOTAG will monitor regulatory developments, investment implications, and how such cross-sector moves shape both markets and scientific research.
